1. Adler H, Gould S, Hine P, Snell LB, Wong W, Houlihan CF, Osborne JC, Rampling T, Beadsworth MBJ, Duncan CJA, Dunning J, Fletcher TE, Hunter ER, Jacobs M, Khoo SH, Newsholme W, Porter D, Porter RJ, Ratcliffe L, Schmid ML, Semple MG, Tunbridge AJ, Wingfield T, Price NM (2022) Clinical features and management of human monkeypox: a retrospective observational study in the UK. Lancet Infect Dis 22:1153–1162. https://doi.org/10.1016/S1473-3099(22)00228-6
2. Andrei G, Snoeck R (2010) Cidofovir activity against poxvirus infections. Viruses 2:2803–2830. https://doi.org/10.3390/v2122803
3. CDC (2022a) Expanded Access IND Protocol: use of tecovirimat (TPOXX®) for treatment of human non-variola orthopoxvirus infections in adults and children (IND No. 116,039). Centers for Disease Control and Prevention, United States. https://www.cdc.gov/poxvirus/monkeypox/pdf/tecovirimat-ind-protocol-cdc-irb.pdf. Accessed: 2 Jan 2023
4. CDC (2022b) Expanded Access IND Protocol: Use of Vaccinia Immune Globulin Intravenous (VIGIV, CNJ-016) for treatment of human Orthopoxvirus infection in adults and children (BB-IND No. 10788). Centers for Disease Control and Prevention, United States. https://www.cdc.gov/poxvirus/monkeypox/pdf/vigiv-ind-protocol.pdf. Accessed: 2 Jan 2023
5. ECDC (2023) Mpox (formerly named monkeypox) situation update, as of 3 January 2022. European Centre for Disease Prevention and Control (ECDC), Stockholm. https://www.ecdc.europa.eu/en/news-events/monkeypox-situation-update. Accessed: 4 Jan 2023